MeiraGTx

Precision AAV gene therapy for the eye, brain, and salivary glands

MeiraGTx is a clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases, neurodegenerative disorders, and xerostomia (dry mouth from radiation). The company has a major collaboration with Johnson & Johnson for ocular gene therapies and has built proprietary manufacturing capabilities for high-quality AAV production. Their lead program for inherited retinal dystrophies has shown durable vision restoration in clinical trials, and their salivary gland gene therapy represents a novel approach to radiation-induced damage.